

TDMS No. 99037 - 06

**P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS
ABRIDGED) (a)**

Date Report Requested: 08/11/2010

Test Type: CHRONIC

alpha/beta Thujone mixture

Time Report Requested: 13:12:57

Route: GAVAGE

CAS Number: THUJONEMIXAB

First Dose M/F: 06/30/03 / 06/30/03

Species/Strain: MICE/B6C3F1

Lab: SRI

F2_M3

C Number: C99037B
Lock Date: 11/20/2006
Cage Range: ALL
Date Range: ALL
Reasons For Removal: 25022 ACCK
25019 MSAC
Removal Date Range: ALL
Treatment Groups: Include ALL
Study Gender: Both
TDMSE Version: 2.2.0

25021 TSAC

25020 NATD

25018 DACC

Test Type: CHRONIC

alpha/beta Thujone mixture

Time Report Requested: 13:12:57

Route: GAVAGE

CAS Number: THUJONEMIXAB

First Dose M/F: 06/30/03 / 06/30/03

Species/Strain: MICE/B6C3F1

Lab: SRI

| B6C3F1 MICE MALE | 0 MG/KG | 3 MG/KG | 6 MG/KG | 12 MG/KG | 25 MG/KG |
|------------------|---------|---------|---------|----------|----------|
|------------------|---------|---------|---------|----------|----------|

Disposition Summary

| | | | | | |
|---|-----------|-----------|-----------|-----------|-----------|
| Animals Initially In Study | 50 | 50 | 50 | 50 | 50 |
| Early Deaths | | | | | |
| Dosing Accident | | 1 | | | |
| Moribund Sacrifice | 3 | | 4 | 4 | |
| Natural Death | 7 | 7 | 5 | 9 | 36 |
| Survivors | | | | | |
| Natural Death | | | | | 1 |
| Terminal Sacrifice | 40 | 42 | 41 | 37 | 13 |
| Animals Examined Microscopically | 50 | 50 | 50 | 50 | 50 |

ALIMENTARY SYSTEM

| | | | | | |
|---|----------|----------|----------|----------|---------|
| Esophagus | (50) | (50) | (50) | (49) | (50) |
| Intestine Small, Duodenum | (48) | (46) | (50) | (46) | (48) |
| Adenoma | | | 1 (2%) | 1 (2%) | |
| Carcinoma | | | 1 (2%) | | |
| Intestine Small, Ileum | (50) | (48) | (48) | (47) | (49) |
| Carcinoma | | | 1 (2%) | 1 (2%) | |
| Intestine Small, Jejunum | (48) | (46) | (49) | (46) | (43) |
| Carcinoma | | 2 (4%) | 2 (4%) | 1 (2%) | |
| Leiomyosarcoma | 1 (2%) | | | | |
| Liver | (50) | (50) | (50) | (50) | (50) |
| Cholangioma | | | | 1 (2%) | |
| Hemangiosarcoma | 2 (4%) | 3 (6%) | 2 (4%) | 1 (2%) | |
| Hepatoblastoma | 2 (4%) | 3 (6%) | 1 (2%) | 2 (4%) | |
| Hepatoblastoma, Multiple | 1 (2%) | | | | |
| Hepatocellular Adenoma | 10 (20%) | 15 (30%) | 16 (32%) | 16 (32%) | 6 (12%) |
| Hepatocellular Adenoma, Multiple | 14 (28%) | 8 (16%) | 14 (28%) | 12 (24%) | 7 (14%) |
| Hepatocellular Carcinoma | 13 (26%) | 18 (36%) | 15 (30%) | 13 (26%) | 2 (4%) |
| Hepatocellular Carcinoma, Multiple | 3 (6%) | 8 (16%) | 8 (16%) | 3 (6%) | 3 (6%) |
| Hepatocholangioma | 1 (2%) | | | | |
| Leiomyosarcoma, Metastatic, Stomach, Glandular | | | | 1 (2%) | |
| Mast Cell Tumor Malignant | | 2 (4%) | | | |

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

alpha/beta Thujone mixture

Time Report Requested: 13:12:57

Route: GAVAGE

CAS Number: THUJONEMIXAB

First Dose M/F: 06/30/03 / 06/30/03

Species/Strain: MICE/B6C3F1

Lab: SRI

| B6C3F1 MICE MALE | 0 MG/KG | 3 MG/KG | 6 MG/KG | 12 MG/KG | 25 MG/KG |
|--|----------|---------|---------|----------|----------|
| Mesentery | (4) | (4) | (3) | (7) | (3) |
| Alveolar/Bronchiolar Carcinoma, Metastatic, Lung | | | 1 (33%) | | |
| Hemangioma | | | | 1 (14%) | |
| Hemangiosarcoma | | 1 (25%) | | | |
| Leiomyosarcoma, Metastatic, Intestine Small, Jejunum | 1 (25%) | | | | |
| Leiomyosarcoma, Metastatic, Stomach, Glandular | | | | 1 (14%) | |
| Sarcoma | | 1 (25%) | | | |
| Pancreas | (50) | (50) | (50) | (50) | (50) |
| Hepatoblastoma, Metastatic, Liver | | | | 1 (2%) | |
| Leiomyosarcoma, Metastatic, Intestine Small, Jejunum | 1 (2%) | | | | |
| Leiomyosarcoma, Metastatic, Stomach, Glandular | | | | 1 (2%) | |
| Sarcoma, Metastatic, Mesentery | | 1 (2%) | | | |
| Salivary Glands | (50) | (50) | (50) | (50) | (50) |
| Stomach, Forestomach | (50) | (50) | (50) | (50) | (50) |
| Squamous Cell Carcinoma | | | | 1 (2%) | |
| Squamous Cell Papilloma | | | 1 (2%) | 1 (2%) | 1 (2%) |
| Stomach, Glandular | (50) | (50) | (50) | (49) | (50) |
| Leiomyosarcoma | | | | 1 (2%) | |
| Mast Cell Tumor Malignant | | | | 1 (2%) | |
| Squamous Cell Carcinoma, Metastatic, Stomach, Forestomach | | | | 1 (2%) | |
| Tongue | (1) | (0) | (0) | (1) | (0) |
| Fibroma | 1 (100%) | | | | |
| CARDIOVASCULAR SYSTEM | | | | | |
| Heart | (50) | (50) | (50) | (50) | (50) |
| Alveolar/Bronchiolar Carcinoma, Metastatic, Lung | | | 2 (4%) | | |
| Hepatoblastoma, Metastatic, Liver | | | | 1 (2%) | |
| Schwannoma Malignant | | | | 1 (2%) | |

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

alpha/beta Thujone mixture
CAS Number: THUJONEMIXAB

Time Report Requested: 13:12:57

Route: GAVAGE

First Dose M/F: 06/30/03 / 06/30/03

Species/Strain: MICE/B6C3F1

Lab: SRI

| B6C3F1 MICE MALE | 0 MG/KG | 3 MG/KG | 6 MG/KG | 12 MG/KG | 25 MG/KG |
|--|----------|----------|----------|----------|----------|
| ENDOCRINE SYSTEM | | | | | |
| Adrenal Cortex | (50) | (50) | (50) | (50) | (50) |
| Leiomyosarcoma, Metastatic, Stomach, Glandular | | | | 1 (2%) | |
| Subcapsular, Adenoma | 2 (4%) | 4 (8%) | 2 (4%) | 5 (10%) | |
| Adrenal Medulla | (49) | (49) | (50) | (50) | (50) |
| Pheochromocytoma Malignant | 1 (2%) | | | | |
| Bilateral, Pheochromocytoma Benign | | 1 (2%) | | | |
| Islets, Pancreatic | (50) | (50) | (50) | (50) | (50) |
| Adenoma | 4 (8%) | 1 (2%) | 1 (2%) | 1 (2%) | 2 (4%) |
| Adenoma, Multiple | | 1 (2%) | | | |
| Parathyroid Gland | (43) | (48) | (47) | (46) | (48) |
| Pituitary Gland | (48) | (50) | (48) | (49) | (49) |
| Pars Distalis, Adenoma | | 1 (2%) | | | |
| Thyroid Gland | (49) | (50) | (50) | (49) | (50) |
| Follicular Cell, Adenoma | 1 (2%) | | | 1 (2%) | |
| Follicular Cell, Carcinoma | 1 (2%) | | | | |
| GENERAL BODY SYSTEM | | | | | |
| Tissue NOS | (1) | (1) | (1) | (1) | (0) |
| Alveolar/Bronchiolar Carcinoma, Metastatic, Lung | | | 1 (100%) | | |
| Hemangiosarcoma | | 1 (100%) | | | |
| Hepatocellular Carcinoma, Metastatic, Liver | 1 (100%) | | | | |
| GENITAL SYSTEM | | | | | |
| Epididymis | (50) | (50) | (50) | (50) | (50) |
| Penis | (1) | (0) | (0) | (1) | (0) |
| Preputial Gland | (49) | (49) | (50) | (50) | (50) |
| Hemangiosarcoma | | 1 (2%) | | | |
| Prostate | (49) | (50) | (50) | (50) | (50) |
| Seminal Vesicle | (50) | (50) | (50) | (50) | (50) |

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

alpha/beta Thujone mixture

Time Report Requested: 13:12:57

Route: GAVAGE

CAS Number: THUJONEMIXAB

First Dose M/F: 06/30/03 / 06/30/03

Species/Strain: MICE/B6C3F1

Lab: SRI

| B6C3F1 MICE MALE | 0 MG/KG | 3 MG/KG | 6 MG/KG | 12 MG/KG | 25 MG/KG |
|---|---------|---------|---------|----------|----------|
| Leiomyosarcoma, Metastatic, Stomach, Glandular | | | | 1 (2%) | |
| Sarcoma, Metastatic, Mesentery | | 1 (2%) | | | |
| Testes | (50) | (50) | (50) | (50) | (50) |
| Interstitial Cell, Adenoma | 1 (2%) | 1 (2%) | 1 (2%) | | |
| HEMATOPOIETIC SYSTEM | | | | | |
| Bone Marrow | (50) | (50) | (50) | (50) | (50) |
| Hemangiosarcoma | | | | 1 (2%) | |
| Mast Cell Tumor Malignant | | 2 (4%) | | | |
| Lymph Node | (3) | (0) | (1) | (1) | (0) |
| Hepatoblastoma, Metastatic, Liver | | | | 1 (100%) | |
| Mediastinal, Hepatoblastoma, Metastatic, Liver | | | | 1 (100%) | |
| Thoracic, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung | 1 (33%) | | | | |
| Lymph Node, Mandibular | (47) | (49) | (46) | (47) | (44) |
| Mast Cell Tumor Malignant | | 1 (2%) | | | |
| Lymph Node, Mesenteric | (49) | (48) | (47) | (47) | (50) |
| Leiomyosarcoma, Metastatic, Stomach, Glandular | | | | 1 (2%) | |
| Plasma Cell Tumor Malignant | 1 (2%) | | | | |
| Spleen | (50) | (50) | (50) | (49) | (50) |
| Hemangiosarcoma | 1 (2%) | | 3 (6%) | | |
| Mast Cell Tumor Malignant | | 2 (4%) | | | |
| Squamous Cell Carcinoma, Metastatic, Stomach, Forestomach | | | | 1 (2%) | |
| Thymus | (44) | (43) | (44) | (40) | (49) |
| Hepatocellular Carcinoma, Metastatic, Liver | 1 (2%) | | | | |
| INTEGUMENTARY SYSTEM | | | | | |
| Skin | (50) | (50) | (50) | (50) | (50) |
| Keratoacanthoma | | | | | 1 (2%) |
| Mast Cell Tumor Malignant | | 1 (2%) | | | |
| Subcutaneous Tissue, Fibroma | | | | 1 (2%) | |

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

alpha/beta Thujone mixture

Time Report Requested: 13:12:57

Route: GAVAGE

CAS Number: THUJONEMIXAB

First Dose M/F: 06/30/03 / 06/30/03

Species/Strain: MICE/B6C3F1

Lab: SRI

| B6C3F1 MICE MALE | 0 MG/KG | 3 MG/KG | 6 MG/KG | 12 MG/KG | 25 MG/KG |
|--|----------|----------|---------|----------|----------|
| Subcutaneous Tissue, Hemangiosarcoma | | 1 (2%) | | 1 (2%) | |
| Subcutaneous Tissue, Osteosarcoma, Metastatic, Uncertain Primary Site | | 1 (2%) | | | |
| MUSCULOSKELETAL SYSTEM | | | | | |
| Bone | (50) | (50) | (50) | (49) | (50) |
| Osteoma | 1 (2%) | | | | |
| Skeletal Muscle | (2) | (1) | (3) | (1) | (0) |
| Hemangiosarcoma | 2 (100%) | | 1 (33%) | | |
| Hepatoblastoma, Metastatic, Liver Sarcoma | | 1 (100%) | | 1 (100%) | |
| NERVOUS SYSTEM | | | | | |
| Brain | (50) | (50) | (50) | (50) | (50) |
| RESPIRATORY SYSTEM | | | | | |
| Lung | (50) | (50) | (50) | (50) | (50) |
| Alveolar/Bronchiolar Adenoma | 7 (14%) | 3 (6%) | 8 (16%) | 6 (12%) | 6 (12%) |
| Alveolar/Bronchiolar Adenoma, Multiple | | 2 (4%) | | | |
| Alveolar/Bronchiolar Carcinoma | 6 (12%) | 4 (8%) | 6 (12%) | 3 (6%) | 1 (2%) |
| Alveolar/Bronchiolar Carcinoma, Multiple | | | 3 (6%) | 1 (2%) | 2 (4%) |
| Hepatoblastoma, Metastatic, Liver | | | | 1 (2%) | |
| Hepatocellular Carcinoma, Metastatic, Liver | 4 (8%) | 8 (16%) | 9 (18%) | 5 (10%) | 1 (2%) |
| Leiomyosarcoma, Metastatic, Intestine Small, Jejunum | 1 (2%) | | | | |
| Schwannoma Malignant, Metastatic, Heart | | | | 1 (2%) | |
| Nose | (50) | (50) | (50) | (50) | (50) |
| Fibroma | | | 1 (2%) | | |
| SPECIAL SENSES SYSTEM | | | | | |

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

alpha/beta Thujone mixture

Time Report Requested: 13:12:57

Route: GAVAGE

CAS Number: THUJONEMIXAB

First Dose M/F: 06/30/03 / 06/30/03

Species/Strain: MICE/B6C3F1

Lab: SRI

| B6C3F1 MICE MALE | 0 MG/KG | 3 MG/KG | 6 MG/KG | 12 MG/KG | 25 MG/KG |
|---|---------|---------|---------|----------|----------|
| Eye | (50) | (50) | (50) | (50) | (50) |
| Harderian Gland | (50) | (50) | (50) | (50) | (49) |
| Adenoma | 8 (16%) | 8 (16%) | 4 (8%) | 1 (2%) | 2 (4%) |
| Carcinoma | 2 (4%) | 2 (4%) | 3 (6%) | 1 (2%) | |
| Bilateral, Adenoma | | 1 (2%) | | | |
| URINARY SYSTEM | | | | | |
| Kidney | (50) | (50) | (50) | (50) | (50) |
| Alveolar/Bronchiolar Carcinoma, Metastatic, Lung | 1 (2%) | | 2 (4%) | | |
| Hepatoblastoma, Metastatic, Liver | | | | 1 (2%) | |
| Renal Tubule, Adenoma | | | 1 (2%) | | |
| Urethra | (0) | (1) | (0) | (0) | (0) |
| Urinary Bladder | (50) | (50) | (50) | (50) | (50) |
| SYSTEMIC LESIONS | | | | | |
| Multiple Organ | *(50) | *(50) | *(50) | *(50) | *(50) |
| Histiocytic Sarcoma | 1 (2%) | 1 (2%) | | | |
| Lymphoma Malignant | 4 (8%) | 2 (4%) | 7 (14%) | 1 (2%) | |

a - Number of animals examined microscopically at site and number of animals with lesion

* Number of animals with any tissue examined microscopically

Test Type: CHRONIC

alpha/beta Thujone mixture

Time Report Requested: 13:12:57

Route: GAVAGE

CAS Number: THUJONEMIXAB

First Dose M/F: 06/30/03 / 06/30/03

Species/Strain: MICE/B6C3F1

Lab: SRI

| | | | | | |
|------------------|---------|---------|---------|----------|----------|
| B6C3F1 MICE MALE | 0 MG/KG | 3 MG/KG | 6 MG/KG | 12 MG/KG | 25 MG/KG |
|------------------|---------|---------|---------|----------|----------|

Tumor Summary for Males

| | | | | | |
|--|----|-----|-----|----|----|
| Total Animals with Primary Neoplasms (b) | 45 | 45 | 46 | 42 | 19 |
| Total Primary Neoplasms | 91 | 103 | 103 | 80 | 33 |
| Total Animals with Benign Neoplasms | 32 | 32 | 36 | 35 | 16 |
| Total Benign Neoplasms | 50 | 46 | 50 | 47 | 25 |
| Total Animals with Malignant Neoplasms | 30 | 33 | 38 | 27 | 7 |
| Total Malignant Neoplasms | 41 | 57 | 53 | 33 | 8 |
| Total Animals with Metastatic Neoplasms | 6 | 10 | 11 | 9 | 1 |
| Total Metastatic Neoplasms | 11 | 11 | 15 | 21 | 1 |
| Total Animals with Malignant Neoplasms Uncertain Primary Site | | 1 | | | |
| Total Animals with Neoplasms Uncertain- Benign or Malignant | | | | | |
| Total Uncertain Neoplasms | | | | | |

*** END OF MALE ***

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

Test Type: CHRONIC

alpha/beta Thujone mixture

Time Report Requested: 13:12:57

Route: GAVAGE

CAS Number: THUJONEMIXAB

First Dose M/F: 06/30/03 / 06/30/03

Species/Strain: MICE/B6C3F1

Lab: SRI

| B6C3F1 MICE FEMALE | 0 MG/KG | 3 MG/KG | 6 MG/KG | 12 MG/KG | 25 MG/KG |
|--------------------|---------|---------|---------|----------|----------|
|--------------------|---------|---------|---------|----------|----------|

Disposition Summary

| | | | | | |
|----------------------------------|----|----|----|----|----|
| Animals Initially In Study | 50 | 50 | 50 | 50 | 50 |
| Early Deaths | | | | | |
| Accidentally Killed | 2 | | | | 1 |
| Dosing Accident | | 6 | | | 4 |
| Moribund Sacrifice | 4 | 4 | 2 | 3 | 8 |
| Natural Death | 7 | 6 | 8 | 6 | 37 |
| Survivors | | | | | |
| Natural Death | | | 1 | | |
| Terminal Sacrifice | 37 | 33 | 39 | 41 | |
| Animals Examined Microscopically | 50 | 49 | 50 | 50 | 50 |

ALIMENTARY SYSTEM

| | | | | | |
|--|----------|---------|---------|---------|------|
| Esophagus | (50) | (48) | (49) | (50) | (50) |
| Gallbladder | (43) | (39) | (43) | (46) | (46) |
| Intestine Large, Cecum | (48) | (46) | (46) | (49) | (49) |
| Intestine Small, Duodenum | (46) | (44) | (45) | (46) | (48) |
| Adenoma | | | | 1 (2%) | |
| Leiomyosarcoma | | 1 (2%) | | | |
| Intestine Small, Ileum | (48) | (47) | (45) | (49) | (48) |
| Intestine Small, Jejunum | (47) | (47) | (45) | (48) | (47) |
| Leiomyosarcoma | | 1 (2%) | | 1 (2%) | |
| Liver | (50) | (49) | (49) | (50) | (50) |
| Hemangiosarcoma | 1 (2%) | | 1 (2%) | | |
| Hepatocellular Adenoma | 10 (20%) | 3 (6%) | 9 (18%) | 5 (10%) | |
| Hepatocellular Adenoma, Multiple | 3 (6%) | 1 (2%) | 2 (4%) | 3 (6%) | |
| Hepatocellular Carcinoma | 2 (4%) | 7 (14%) | 3 (6%) | | |
| Hepatocellular Carcinoma, Multiple | 1 (2%) | | | | |
| Plasma Cell Tumor Malignant | 1 (2%) | | | | |
| Mesentery | (10) | (6) | (5) | (6) | (0) |
| Hemangioma | | | 1 (20%) | | |
| Hemangiosarcoma | | | 1 (20%) | | |
| Leiomyosarcoma, Metastatic, Intestine Small, Jejunum | | | | 1 (17%) | |

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

alpha/beta Thujone mixture

Time Report Requested: 13:12:57

Route: GAVAGE

CAS Number: THUJONEMIXAB

First Dose M/F: 06/30/03 / 06/30/03

Species/Strain: MICE/B6C3F1

Lab: SRI

| B6C3F1 MICE FEMALE | 0 MG/KG | 3 MG/KG | 6 MG/KG | 12 MG/KG | 25 MG/KG |
|--|---------|---------|---------|----------|----------|
| Schwannoma Malignant, Metastatic, Skin | 1 (10%) | | | | |
| Pancreas | (48) | (49) | (48) | (50) | (50) |
| Sarcoma, Metastatic, Skin | | 1 (2%) | | | |
| Salivary Glands | (49) | (48) | (49) | (50) | (50) |
| Stomach, Forestomach | (50) | (49) | (48) | (50) | (50) |
| Hemangioma | | | 1 (2%) | | |
| Stomach, Glandular | (48) | (49) | (47) | (48) | (50) |
| Tongue | (0) | (0) | (0) | (0) | (1) |

CARDIOVASCULAR SYSTEM

| | | | | | |
|-------|------|------|------|------|------|
| Heart | (50) | (49) | (50) | (50) | (50) |
|-------|------|------|------|------|------|

ENDOCRINE SYSTEM

| | | | | | |
|-----------------------------|--------|--------|--------|--------|------|
| Adrenal Cortex | (50) | (49) | (49) | (50) | (50) |
| Adenoma | 1 (2%) | | | | |
| Plasma Cell Tumor Malignant | 1 (2%) | | | | |
| Adrenal Medulla | (50) | (47) | (46) | (48) | (49) |
| Pheochromocytoma Benign | | 1 (2%) | 1 (2%) | | |
| Islets, Pancreatic | (48) | (49) | (48) | (50) | (50) |
| Adenoma | 1 (2%) | 1 (2%) | | | |
| Parathyroid Gland | (45) | (42) | (46) | (47) | (49) |
| Pituitary Gland | (49) | (48) | (48) | (49) | (47) |
| Pars Distalis, Adenoma | 2 (4%) | 3 (6%) | 3 (6%) | | |
| Pars Intermedia, Adenoma | | | 1 (2%) | | |
| Pars Intermedia, Carcinoma | | | | 1 (2%) | |
| Thyroid Gland | (50) | (48) | (48) | (49) | (49) |
| Follicular Cell, Adenoma | | | 1 (2%) | | |

GENERAL BODY SYSTEM

| | | | | | |
|-----------------------------|----------|-----|-----|-----|-----|
| Tissue NOS | (1) | (0) | (0) | (0) | (0) |
| Plasma Cell Tumor Malignant | 1 (100%) | | | | |

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

alpha/beta Thujone mixture

Time Report Requested: 13:12:57

Route: GAVAGE

CAS Number: THUJONEMIXAB

First Dose M/F: 06/30/03 / 06/30/03

Species/Strain: MICE/B6C3F1

Lab: SRI

| B6C3F1 MICE FEMALE | 0 MG/KG | 3 MG/KG | 6 MG/KG | 12 MG/KG | 25 MG/KG |
|--------------------|---------|---------|---------|----------|----------|
|--------------------|---------|---------|---------|----------|----------|

GENITAL SYSTEM

| | | | | | |
|-----------------------------|--------|--------|--------|--------|------|
| Clitoral Gland | (48) | (46) | (48) | (49) | (47) |
| Ovary | (48) | (47) | (49) | (48) | (50) |
| Choriocarcinoma | 1 (2%) | | | | |
| Cystadenoma | 2 (4%) | | 4 (8%) | 3 (6%) | |
| Granulosa Cell Tumor Benign | | 1 (2%) | | | |
| Hemangiosarcoma | | | 1 (2%) | | |
| Luteoma | | | 2 (4%) | 1 (2%) | |
| Plasma Cell Tumor Malignant | 1 (2%) | | | | |
| Uterus | (50) | (49) | (50) | (50) | (50) |
| Leiomyosarcoma | | 1 (2%) | | 1 (2%) | |
| Polyp Stromal | 1 (2%) | 1 (2%) | 1 (2%) | | |
| Sarcoma Stromal | | 1 (2%) | | | |

HEMATOPOIETIC SYSTEM

| | | | | | |
|--|---------|---------|--------|--------|------|
| Bone Marrow | (50) | (49) | (49) | (50) | (50) |
| Hemangiosarcoma | 1 (2%) | | 1 (2%) | | |
| Mast Cell Tumor Benign | | | | 1 (2%) | |
| Plasma Cell Tumor Malignant | 1 (2%) | | | | |
| Lymph Node | (6) | (3) | (3) | (1) | (0) |
| Plasma Cell Tumor Malignant | 1 (17%) | | | | |
| Bronchial, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung | | 1 (33%) | | | |
| Mediastinal, Plasma Cell Tumor Malignant | 1 (17%) | | | | |
| Lymph Node, Mandibular | (48) | (46) | (45) | (48) | (49) |
| Plasma Cell Tumor Malignant | 1 (2%) | | | | |
| Lymph Node, Mesenteric | (46) | (49) | (46) | (48) | (47) |
| Plasma Cell Tumor Malignant | 1 (2%) | | | | |
| Spleen | (50) | (49) | (48) | (50) | (50) |
| Hemangiosarcoma | 1 (2%) | | 2 (4%) | | |
| Plasma Cell Tumor Malignant | 1 (2%) | | | | |
| Thymus | (46) | (45) | (46) | (48) | (49) |

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

alpha/beta Thujone mixture

Time Report Requested: 13:12:57

Route: GAVAGE

CAS Number: THUJONEMIXAB

First Dose M/F: 06/30/03 / 06/30/03

Species/Strain: MICE/B6C3F1

Lab: SRI

| B6C3F1 MICE FEMALE | 0 MG/KG | 3 MG/KG | 6 MG/KG | 12 MG/KG | 25 MG/KG |
|--|---------|----------|---------|----------|----------|
| Fibrosarcoma, Metastatic, Skin | | | 1 (2%) | | |
| INTEGUMENTARY SYSTEM | | | | | |
| Mammary Gland | (50) | (49) | (50) | (50) | (50) |
| Adenoma | | | | 1 (2%) | |
| Carcinoma | 1 (2%) | 1 (2%) | | | |
| Skin | (50) | (49) | (50) | (50) | (50) |
| Leiomyosarcoma, Metastatic, Intestine Small, Jejunum | | 1 (2%) | | | |
| Subcutaneous Tissue, Fibrosarcoma | 2 (4%) | 4 (8%) | 1 (2%) | | |
| Subcutaneous Tissue, Hemangiosarcoma | 1 (2%) | | 1 (2%) | | |
| Subcutaneous Tissue, Sarcoma | 1 (2%) | 1 (2%) | 1 (2%) | 1 (2%) | |
| Subcutaneous Tissue, Schwannoma Malignant | 1 (2%) | | | 1 (2%) | |
| MUSCULOSKELETAL SYSTEM | | | | | |
| Bone | (50) | (49) | (50) | (50) | (50) |
| Skeletal Muscle | (3) | (2) | (0) | (0) | (0) |
| Rhabdomyosarcoma | 1 (33%) | | | | |
| Sarcoma | | 2 (100%) | | | |
| Schwannoma Malignant, Metastatic, Skin | 1 (33%) | | | | |
| NERVOUS SYSTEM | | | | | |
| Brain | (50) | (49) | (50) | (50) | (50) |
| Carcinoma, Metastatic, Pituitary Gland | | | | 1 (2%) | |
| Cranial Nerve, Schwannoma Malignant | 1 (2%) | | | | |
| RESPIRATORY SYSTEM | | | | | |
| Lung | (50) | (49) | (50) | (50) | (50) |
| Alveolar/Bronchiolar Adenoma | 2 (4%) | 4 (8%) | 2 (4%) | 2 (4%) | |
| Alveolar/Bronchiolar Adenoma, Multiple | 1 (2%) | | | | |

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

alpha/beta Thujone mixture
CAS Number: THUJONEMIXAB

Time Report Requested: 13:12:57

Route: GAVAGE

First Dose M/F: 06/30/03 / 06/30/03

Species/Strain: MICE/B6C3F1

Lab: SRI

| B6C3F1 MICE FEMALE | 0 MG/KG | 3 MG/KG | 6 MG/KG | 12 MG/KG | 25 MG/KG |
|---|---------|---------|---------|----------|----------|
| Alveolar/Bronchiolar Carcinoma | 1 (2%) | 3 (6%) | 2 (4%) | 1 (2%) | |
| Alveolar/Bronchiolar Carcinoma, Multiple | | | 1 (2%) | | |
| Carcinoma, Metastatic, Harderian Gland | | | 1 (2%) | 1 (2%) | |
| Carcinoma, Metastatic, Uncertain Primary Site | | | | 1 (2%) | |
| Fibrosarcoma, Metastatic, Skin | 1 (2%) | | 1 (2%) | | |
| Plasma Cell Tumor Malignant | 1 (2%) | | | | |
| Nose | (50) | (49) | (50) | (50) | (50) |
| Pleura | (0) | (0) | (0) | (0) | (4) |
| Trachea | (50) | (49) | (50) | (50) | (50) |

SPECIAL SENSES SYSTEM

| | | | | | |
|--|---------|--------|---------|---------|--------|
| Eye | (50) | (49) | (50) | (50) | (50) |
| Carcinoma, Metastatic, Harderian Gland | | | 1 (2%) | 1 (2%) | |
| Harderian Gland | (50) | (49) | (50) | (49) | (50) |
| Adenoma | 5 (10%) | 1 (2%) | 5 (10%) | 9 (18%) | 1 (2%) |
| Carcinoma | 1 (2%) | 2 (4%) | 4 (8%) | 3 (6%) | |

URINARY SYSTEM

| | | | | | |
|-----------------------------|--------|------|------|------|------|
| Kidney | (50) | (49) | (49) | (50) | (50) |
| Plasma Cell Tumor Malignant | 1 (2%) | | | | |
| Urinary Bladder | (50) | (49) | (49) | (50) | (50) |
| Plasma Cell Tumor Malignant | 1 (2%) | | | | |

SYSTEMIC LESIONS

| | | | | | |
|------------------------|---------|---------|----------|----------|-------|
| Multiple Organ | *(50) | *(49) | *(50) | *(50) | *(50) |
| Histiocytic Sarcoma | 2 (4%) | 2 (4%) | | 4 (8%) | |
| Lymphoma Malignant | 6 (12%) | 9 (18%) | 13 (26%) | 13 (26%) | |
| Mesothelioma Malignant | | | 1 (2%) | | |

a - Number of animals examined microscopically at site and number of animals with lesion

* Number of animals with any tissue examined microscopically

Test Type: CHRONIC

alpha/beta Thujone mixture

Time Report Requested: 13:12:57

Route: GAVAGE

CAS Number: THUJONEMIXAB

First Dose M/F: 06/30/03 / 06/30/03

Species/Strain: MICE/B6C3F1

Lab: SRI

| | | | | | |
|--------------------|---------|---------|---------|----------|----------|
| B6C3F1 MICE FEMALE | 0 MG/KG | 3 MG/KG | 6 MG/KG | 12 MG/KG | 25 MG/KG |
|--------------------|---------|---------|---------|----------|----------|

Tumor Summary for Females

| | | | | | |
|--|--------|--------|--------|--------|-------|
| Total Animals with Primary Neoplasms (b) | 35 | 31 | 36 | 34 | 1 |
| Total Primary Neoplasms | 66 | 51 | 66 | 52 | 1 |
| Total Animals with Benign Neoplasms | 22 | 14 | 23 | 19 | 1 |
| Total Benign Neoplasms | 28 | 16 | 33 | 26 | 1 |
| Total Animals with Malignant Neoplasms | 19 | 25 | 25 | 24 | |
| Total Malignant Neoplasms | 38 | 35 | 33 | 26 | |
| Total Animals with Metastatic Neoplasms | 2 | 3 | 2 | 4 | |
| Total Metastatic Neoplasms | 3 | 3 | 4 | 5 | |
| Total Animals with Malignant Neoplasms Uncertain Primary Site | | | | 1 | |
| Total Animals with Neoplasms Uncertain- Benign or Malignant | | | | | |
| Total Uncertain Neoplasms | | | | | |

*** END OF REPORT ***

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors